FGFR
Fibroblast growth factor receptor

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.
# FGFR Inhibitors & Agonists

## 2,5-Dihydroxybenzoic acid

Cat. No.: HY-W001179

2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of fibroblast growth factors.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.97%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 100 mg</td>
</tr>
</tbody>
</table>

## Alofanib (RPT835)

Cat. No.: HY-17601

Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.83%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

## AZD4547

Cat. No.: HY-133030

AZD4547 is a potent inhibitor of the FGFR family with IC_{50} values of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.80%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</td>
</tr>
</tbody>
</table>

## CHS183284 (Debio 1347)

Cat. No.: HY-19957

CHS183284 is an orally available and selective FGFR inhibitor with IC_{50} values of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.73%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
</tbody>
</table>

## CP-547632 hydrochloride

Cat. No.: HY-133028

CP-547632 hydrochloride is a well-tolerated, orally-bioavailable inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases with IC_{50} values of 11 nM and 9 nM, respectively.

<table>
<thead>
<tr>
<th>Purity</th>
<th>&gt;98%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

## ACTB-1003

Cat. No.: HY-16025

ACTB-1003 is an oral kinase inhibitor with IC_{50} values of 6, 2 and 4 nM for FGFR1, VEGFR2, and Tie-2.

<table>
<thead>
<tr>
<th>Purity</th>
<th>97.65%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

## ASP5878

Cat. No.: HY-19983

ASPS878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC_{50} values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.71%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

## BLU9931

Cat. No.: HY-12823

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with an IC_{50} of 3 nM.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.33%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

## Derazantinib (ARQ-087)

Cat. No.: HY-19981

Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor, exhibits potent activity against FGFR1-3 chondrocytes with IC_{50} values of 4.5, 1.8, and 4.5 nM, respectively.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.06%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Size</td>
<td>10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>
Dovitinib
(CHIR-258, TKI258) Cat. No.: HY-50905

Dovitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀ of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-KIT, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.

Purity: 97.18%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

ENMD-2076
Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀ of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.

Purity: 99.23%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ERdafitinib
(JNJ-42756493) Cat. No.: HY-18708

ERdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC₅₀ of 1.2, 2.5, 3.0 and 5.7 nM, respectively.

Purity: 99.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FGFR1/DDR2 inhibitor 1
Cat. No.: HY-114311

FGFR1/DDR2 inhibitor 1 (compound 11k) is an inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoind domain receptor 2 (DDR2), with IC₅₀ values of 31.1 nM, 108.4 nM and 3.2 nM for FGFR1, KG-1, and DDR2, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FIIN-2
Cat. No.: HY-18602

FIIN-2 is an irreversible inhibitor of FGFR with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

FIIN-3
Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of FGFR with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com
**Fisogatinib (BLU-554)**  
Cat. No.: HY-100492  
Fisogatinib (BLU-554) is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.  
Purity: 99.84%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg  

---

**Formononetin**  
(Biochanin B; Flavosil; Formononetol)  
Cat. No.: HY-N0183  
Formononetin (Formononetin; Flavosil) is a bioactive component extracted from the red clover; inhibits the proliferation of DU-145/PC-3 cells in a dose-dependent manner.  
Purity: 99.69%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg  

---

**Futibatinib (TAS-120)**  
Cat. No.: HY-100818  
Futibatinib (TAS-120) is a potent FGFR inhibitor, used for antitumor treatment.  
Purity: 98.80%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg  

---

**Heparan Sulfate**  
Cat. No.: HY-101916  
Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg, 10 mg, 25 mg  

---

**Infigratinib phosphate**  
(BGI-398 phosphate; NVP-BGJ398 (phosphate))  
Cat. No.: HY-13311A  
Infigratinib phosphate (BGI-398 phosphate) is a potent inhibitor of the FGFR family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.  
Purity: 97.74%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg  

---

**Fisogatinib (BLU-554)**  
Cat. No.: HY-10981  
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.  
Purity: 99.74%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg  

---

**Formononetin**  
(Biochanin B; Flavosil; Formononetol)  
Cat. No.: HY-N0183  
Formononetin (Formononetin; Flavosil) is a bioactive component extracted from the red clover; inhibits the proliferation of DU-145/PC-3 cells in a dose-dependent manner.  
Purity: 99.69%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg  

---

**Futibatinib (TAS-120)**  
Cat. No.: HY-100818  
Futibatinib (TAS-120) is a potent FGFR inhibitor, used for antitumor treatment.  
Purity: 98.80%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg  

---

**Heparan Sulfate**  
Cat. No.: HY-101916  
Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg, 10 mg, 25 mg  

---

**Infigratinib**  
(BGI-398; NVP-BGJ398)  
Cat. No.: HY-13311  
Infigratinib (BGI-398) is a potent inhibitor of the FGFR family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.  
Purity: 99.16%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg  

---

**KW-2449**  
Cat. No.: HY-10339  
KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL(T315I) and Aurora kinase with IC₅₀ of 6.6, 14, 4 and 48 nM, respectively.  
Purity: 99.85%  
Clinical Data: Phase 1  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg  

---

**Infigratinib phosphate**  
(BGI-398 phosphate; NVP-BGJ398 (phosphate))  
Cat. No.: HY-13311A  
Infigratinib phosphate (BGI-398 phosphate) is a potent inhibitor of the FGFR family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.  
Purity: 97.74%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg  

---

**Lenvatinib mesylate**  
(E7080 mesylate)  
Cat. No.: HY-10981A  
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.  
Purity: >98%  
Clinical Data: 1 mg, 5 mg  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg
**Lucitanib (E-3810)**  
Cat. No.: HY-15391

Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC_{50} of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

| Purity: 98.24% | Clinical Data: Phase 3 | Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg |

**LY2874455**  
Cat. No.: HY-13304

LY2874455 is a pan-FGFR inhibitor with IC_{50} of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

| Purity: 98.02% | Clinical Data: Phase 1 | Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

**Nintedanib (BIBF 1120)**  
Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFra/β with IC_{50} of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

| Purity: 99.97% | Clinical Data: Launched | Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

**Nintedanib esylate (BIBF 1120 (esylate))**  
Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFra/β with IC_{50} of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

| Purity: 99.95% | Clinical Data: Launched | Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

**ODM-203**  
Cat. No.: HY-119367

ODM-203 is a potent FGFR and VEGFR families inhibitor with IC_{50} of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. ODM-203 exhibits strong anti-tumor activity and induces anti-tumor immunity.

| Purity: > 98% | Clinical Data: No Development Reported | Size: 100 mg, 250 mg, 500 mg |

**Orantinib (SU6668; TSU-68)**  
Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_{i} of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFra and FGFR1, respectively.

| Purity: 99.02% | Clinical Data: Phase 3 | Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

**Pazopanib (GW786034)**  
Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFra, c-Kit, FGFR1, and c-fms with IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

| Purity: 99.68% | Clinical Data: Launched | Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

**Pazopanib Hydrochloride (GW786034 Hydrochloride)**  
Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFra, c-Kit, FGFR1, and c-fms with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

| Purity: 99.83% | Clinical Data: Launched | Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

**PD-166866**  
Cat. No.: HY-101296

PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC_{50} of 52.4 nM.

| Purity: 99.97% | Clinical Data: No Development Reported | Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

**PD173074**  
Cat. No.: HY-10321

PD173074 is a potent FGFR1 inhibitor with an IC_{50} of 25 nM and also inhibits VEGFR2 with an IC_{50} of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGF and c-Src.

| Purity: 99.55% | Clinical Data: No Development Reported | Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg |

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pemigatinib</td>
<td>HY-109099</td>
<td>A selective FGFR inhibitor in development for the treatment of patients with cholangiocarcinoma.</td>
<td>98.95%</td>
<td>No Development Reported</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>PF-05231023</td>
<td>HY-113697</td>
<td>A long-acting fibroblast growth factor 21 (FGF21) analog, suitable for development as a potential treatment for T2DM.</td>
<td>99.78%</td>
<td>No Development Reported</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Ponatinib</td>
<td>HY-12047</td>
<td>A potent, orally available multi-targeted kinase inhibitor with IC_{50} values of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.</td>
<td>99.13%</td>
<td>Launched</td>
<td>10 mM × 1 mL, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>PP58</td>
<td>HY-18622</td>
<td>A pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR, and Src family activities with nanomolar IC_{50} values.</td>
<td>98.07%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>PRN1371</td>
<td>HY-101768</td>
<td>A highly selective and potent FGFR1-4 and CSF1R inhibitor with IC_{50} values of 0.6, 1.3, 4.1, 19.3, and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4, and CSF1R, respectively.</td>
<td>99.24%</td>
<td>Phase 1</td>
<td>10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Roblitinib</td>
<td>HY-101568</td>
<td>An inhibitor of FGFR4 extracted from patent WO2015059668A1, compound example 83; has an IC_{50} of 1.9 nM.</td>
<td>98.08%</td>
<td>Phase 2</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Rogaratinib</td>
<td>HY-100019</td>
<td>A potent and selective fibroblast growth factor receptor (FGFR) inhibitor.</td>
<td>99.38%</td>
<td>No Development Reported</td>
<td>10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>S49076</td>
<td>HY-12965</td>
<td>A novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC_{50} values below 20 nM.</td>
<td>98.99%</td>
<td>No Development Reported</td>
<td>10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>SKLB610</td>
<td>HY-18199</td>
<td>A VEGFR inhibitor with potent anti-tumor activity.</td>
<td>98.96%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>SSR128129E</td>
<td>HY-15599</td>
<td>An orally available and allosteric FGFR inhibitor with an IC_{50} of 1.9 μM for FGFR1.</td>
<td>99.65%</td>
<td>Phase 3</td>
<td>10 mM × 1 mL, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Compound Name</td>
<td>Cat. No.</td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSR128129E free acid</td>
<td>HY-15599A</td>
<td>SSR128129E free acid is an orally available and allosteric FGFR inhibitor with an IC&lt;sub&gt;50&lt;/sub&gt; of 1.9 μM for FGFR1.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SU 5402</td>
<td>HY-10407</td>
<td>SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC&lt;sub&gt;50&lt;/sub&gt; of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfatinib</td>
<td>HY-12297</td>
<td>Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC&lt;sub&gt;50&lt;/sub&gt;s of in a range of 1 to 24 nM.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUN11602</td>
<td>HY-101493</td>
<td>SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG 100572</td>
<td>HY-10184</td>
<td>TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC&lt;sub&gt;50&lt;/sub&gt;s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG 100801 Hydrochloride</td>
<td>HY-10187</td>
<td>TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyrosine kinase-IN-1</td>
<td>HY-100315</td>
<td>Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC&lt;sub&gt;50&lt;/sub&gt;s of 4, 20, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>